Novel potential therapies for septic shock

Shock

Volumn 30, Issue SUPPL. 1, 2008, Pages 60-66

  Azevedo, Luciano Cesar Pontes ^a,b   Park, Marcelo ^a,b   Schettino, Guilherme Paula Pinto ^a  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hemofiltration; Immunoglobulin; Sepsis; Statin; Therapy; Vasopressin

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN C; VASOPRESSIN;

ANTIBACTERIAL ACTIVITY; CONFERENCE PAPER; DISEASE ASSOCIATION; HEMODYNAMICS; HEMOFILTRATION; HUMAN; HYPOTENSION; HYPOXEMIA; INFLAMMATION; LUNG VENTILATION; SEPSIS; SEPTIC SHOCK;

ANIMALS; CLINICAL TRIALS AS TOPIC; HEMOFILTRATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOGLOBULINS; INFLAMMATION; MODELS, BIOLOGICAL; SEPSIS; SHOCK, SEPTIC; TREATMENT OUTCOME; VASOPRESSINS;

EID: 54049121020     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318181a425     Document Type: Conference Paper

References (54)

1. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348(16):1546-1554, 2003.
2. Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 365(9453):63-78, 2005.
3. Russell JA: Management of sepsis. New Engl J Med 355(16):1699-1713, 2006.
4. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34(1):17-60, 2008.
5. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345(19):1368-1377, 2001.
6. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34(6):1589-1596, 2006.
7. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345(19): 1359-1367, 2001.
8. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R: Intensive insulin therapy in the medical ICU. New Engl J Med 354(5):449-461, 2006.
9. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, et al.: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358(2): 125-139, 2008.
10. Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Heiterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699-709, 2001.
11. Annane D, Cavaillon JM: Corticosteroids in sepsis: from bench to bedside? Shock 20(3):197-207, 2003.
12. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. J Am Med Assoc 288(7):862-871, 2002.
13. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, et al.: Hydrocortisone therapy for patients with septic shock. N Engl J Med 358(2):111-124, 2008.
14. Treschan TA, Peters J: The vasopressin system: physiology and clinical strategies. Anesthesiology 105(3):599-612, 2006.
15. Barrett LK, Singer M, Clapp LH: Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 35(1):33-40, 2007.
16. Holmes CL, Patel BM, Russell JA, Walley KR: Physiology of vasopressin relevant to management of septic shock. Chest 120(3):989-1002, 2001.
17. Birnbaumer M: Vasopressin receptors. Trends Endocrinol Metab 11(10): 406-410, 2000.
18. Williams TD, Da Costa D, Mathias CJ, Bannister R, Lightman SL: Pressor effect of arginine vasopressin in progressive autonomic failure. Clin Sci (Lond) 71(2):173-178, 1986.
19. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95(5):1122-1125, 1997.
20. Reid IA: Role of nitric oxide in the regulation of renin and vasopressin secretion. Front Neuroendocrinol 15(4):351-383, 1994.
21. Luckner G, Dünser MW, Jochberger S, Mayr VD, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, et al.: Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 33(11): 2659-2666, 2005.
22. Lauzier F, Lévy B, Lamarre P, Lesur O: Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 32(11):1782-1789, 2006.
23. O'Brien A, Clapp L, Singer M: Terlipressin for norepinephrine-resistant septic shock. Lancet 359(9313):1209-1210, 2002.
24. Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C: Terlipressin in catecholamine-resistant septic shock patients. Shock 22(4): 314-319, 2004.
25. Hollenberg SM: Vasopressor support in septic shock. Chest 132(5):1678-1687, 2007.
26. Forni LG, Hilton PJ: Continuous hemofiltration in the treatment of acute renal failure. N Engl J Med 336(18):1303-1309, 1997.
27. Ronco C, Ricci Z, Bellomo R: Importance of increased ultrafiltration volume and impact on mortality: sepsis and cytokine story and the role of continuous veno-venous haemofiltration. Curr Opin Nephrol Hypertens 10(6):755-761, 2001.
28. Bouman CS, Oudemans-van Straaten HM, Schultz MJ, Vroom MB: Hemofiltration in sepsis and systemic inflammatory response syndrome: the role of dosing and timing. J Crit Care 22(1):1-12, 2007.
29. Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J: Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intensive Care Med 23(8):878-884, 1997.
30. Rogiers P, Zhang H, Pauwels D, Vincent JL: Comparison of polyacrylonitrile (AN69) and polysulphone membrane during hemofiltration in canine endotoxic shock. Crit Care Med 31(4):1219-1225, 2003.
31. Vinsonneau C, Camus C, Combes A, Costa de Beauregard MA, Klouche K, Boulain T, Pallot J-L, Chiche J-D, Taupin P, Landais P, et al.: Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet 3689(9533):379-385, 2006.
32. Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, Ronco C: A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 30(1):100-106, 2002.
33. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356(9223):26-30, 2000.
34. Saudan P, Niederberger M, De Seigneux S, Romand J, Pugin J, Pemeger T, Martin PY: Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int 70(7):1312-1317, 2006.
35. Ratanarat R, Brendolan A, Piccinni P, Dan M, Salvatori G, Ricci Z, Ronco C: Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival. Crit Care 9(4):R294-R302, 2005.
36. Terblanche M, Almog Y, Rosensom RS, Smith TS, Hackam DG: Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 7(5):358-368, 2007.
37. Chua D, Tsang RS, Kuo IF: The role of statin therapy in sepsis. Ann Pharmacother 41(4):647-652, 2007.
38. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, et al.: Simvastatin has antiinflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21(1):115-121, 2001.
39. Rosenson RS, Tangney CC, Casey LC: Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353(9157):983-984, 1999.
40. Durant R, Klouche K, Delbosc S, Morena M, Amigues L, Beraud JJ, Canaud B, Cristol JP: Superoxide anion overproduction in sepsis: effects of vitamin E and simvastatin. Shock 22:34-39, 2004.
41. Giusti-Paiva A, Martinez MR, Felix JVC, Rocha MJA, Carnio EC, Elias LLK, Antunes-Rodrigues J: Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock 21(3):271-275, 2004.
42. Merx MW, Liehn EA, Graf J, van de Sandt A, Schaltenbrand M, Schrader J, Hanrath P, Weber C: Statin treatment after onset of sepsis in a murine model improves survival. Circulation 112(1):117-124, 2005.
43. Liappis AP, Kan VL, Rochester CG, Simon GL: The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33(8):1352-1357, 2001.
44. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A: Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110(7):880-885, 2004.
45. Almog Y, Novack V, Eisinger M, Porath A, Novack L, Gilutz H: The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 35(2):372-378, 2007.
46. Jolles S, Sewell WAC, Misbah SA: Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142(1):1-11, 2005.
47. Norbby-Teglund A, Haque KN, Hammarstrom L: Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological etiology and severity of sepsis. J Int Med 260(6): 509-516, 2006.
48. Werdan K: Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr Opin Crit Care 7(5):354-361, 2001.
49. Hoffmann J, Fertmann JM, Vollmar B, Laschke MW, Jauch KW, Menger MD: Immunoglobulin M-enriched human intravenous immunoglobulins reduce leukocyte-endothelial interactions and attenuate microvascular perfusion failure in normotensive endotoxemia. Shock 29(1):133-139, 2008.
50. Kaul R, Mcgeer A, Norbby-Teglund A, Kotb M, Schwartz B, O'Rourke K, Talbot J, Low DE: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. Clin Infect Dis 28(4): 800-807, 1999.
51. Werdan K, Pilz G, SBITS Study Group: Polyvalent immune globulins. Shock 7(Suppl): Abstract 5/1918, 1997.
52. Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, Ubelacker R, Buchheidt D, Behre G, Hiddemann W, et al.: IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 34(5):1319-1325, 2006.
53. Turgeon AF, Hutton B, Fergusson DA, McIntyre L, Tinmouth AA, Cameron W, Hebert PC: Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 146(3):193-203, 2007.
54. El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, Boshra N: Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. J Trop Pediatr 51(5): 271-278, 2005.